BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21883838)

  • 1. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
    Segal R; Yafi FA; Brimo F; Tanguay S; Aprikian A; Kassouf W
    BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
    Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
    Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder.
    Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB
    J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME; Bastian PJ; Palapattu GS; Trock BJ; Schoenberg MP; Chan T; Rogers CG
    Urology; 2007 Dec; 70(6):1091-5. PubMed ID: 18158024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.